Federal cannabis policy saw some notable updates last week, though you might have missed it if you weren’t reading the fine print of congressional appropriations. The U.S. House of Representatives passed a massive spending package that does two critical things for the marijuana industry: it maintains the shield protecting state-level medical programs and, perhaps more surprisingly, drops the sword that was intended to kill federal rescheduling efforts.
For years, the tension between state legalization and federal prohibition has played out in the annual budget battles. This year, however, the dynamic is different. Following a 397-28 vote last Thursday, the House advanced H.R. 6938, a “minibus” appropriations bill funding the Departments of Commerce and Justice.
Buried within the legislative text are signals that Congress is aligning with the Executive Branch to finally move the needle on cannabis reform. By examining what was included—and crucially, what was omitted—we can see a clear path forming toward the reclassification of marijuana.
The “Minibus” and the Vote
The bill, H.R. 6938, covers fiscal year 2026 spending for Commerce, Justice, Science, and Related Agencies (CJS). In Washington, money is policy. If the government isn’t funded to enforce a law, that law effectively goes dormant. This is exactly how the cannabis industry has survived in a gray area for over a decade.
The House passed this legislation with overwhelming bipartisan support. While budget votes are often routine, this specific package carries heavy implications for the drug policy agenda of the current administration. It signals that the House is willing to fund the status quo regarding medical marijuana protections while simultaneously stepping out of the way of the Justice Department’s rescheduling process.
Section 531: The Shield for Medical Marijuana
The most immediate win for the industry is the inclusion of Section 531. This provision is the modern iteration of what was formerly known as the Rohrabacher-Farr amendment. It is a legislative rider that strictly prohibits the Department of Justice (DOJ) from using federal funds to interfere with the implementation of state medical marijuana laws.
Without this rider, the DOJ could technically raid state-compliant dispensaries and prosecute patients, even in states where medical cannabis has been legal for years. Section 531 specifically lists the states and territories where the DOJ must stand down.
Nebraska’s Exclusion
However, the protection is not universal. A close reading of the text reveals a notable exclusion. While the rider lists dozens of states from Alabama to Wyoming, along with territories like Puerto Rico and Guam, it explicitly excludes Nebraska.
The bill’s authors have not clarified why they excluded Nebraska from the list of protected jurisdictions.
Omission of Section 607
While the inclusion of medical protections was expected, the real headline lies in what was left out, as first pointed out by Marijuana Moment. Previous drafts of this spending bill, specifically those advanced by the House Appropriations Committee last year, included a “poison pill” known as Section 607.
Designed as a blockade, Section 607 explicitly prohibited the use of any appropriated funds to reschedule marijuana or remove it from the Controlled Substances Act (CSA) schedules.
If passed, Section 607 would have effectively frozen the Drug Enforcement Administration (DEA) and the DOJ in place, legally preventing them from moving marijuana from Schedule I to Schedule III. It was a legislative attempt to override the administrative process of rescheduling.
The final version of H.R. 6938 passed by the House completely omits this language.
The removal of Section 607 is not an accident. In the context of legislative drafting, removing a specific prohibition is a tacit endorsement—or at least an agreement not to obstruct—the activity in question. By stripping this language, the House has cleared the runway for the Department of Justice to proceed with rescheduling marijuana.
The Trump Executive Order Connection
To understand why the House suddenly dropped its opposition to federal rescheduling, we have to look at the timeline. On December 18, 2025, President Donald Trump signed an executive order directing Attorney General Pam Bondi to “expedite completion” of the process to move marijuana to Schedule III.
Prior to the Executive Order, conservative lawmakers in the House viewed rescheduling as a policy tied to the previous Biden administration. Blocking it via Section 607 was a way to stall a Democratic policy win.
Once President Trump took charge of the issue and directed his Attorney General to act, opposition within his party becomes politically challenging. The House likely omitted the blocking language in H.R. 6938 to align with the President’s directive.
The President’s order noted the need to research medical benefits and focus on long-term health effects. By removing the legislative blockade, Congress is effectively stepping aside to let AG Bondi fulfill that executive mandate.
What This Means for Rescheduling
With the legislative “stop sign” removed, the path to Schedule III is clearer than it has been in years. The process, currently overseen by the DOJ and DEA, faces fewer hurdles.
Despite the President’s order to expedite, the DEA noted earlier this week that the federal rescheduling appeal process “remains pending.” Administrative law judges and bureaucratic procedures still need to be navigated. However, without the threat of a Congressional funding ban hanging over their heads, agency officials have the green light to proceed.
The passage of H.R. 6938 is a significant milestone, but it is not the finish line. The bill now heads to the Senate for consideration. The bipartisan House vote and alignment with the White House suggest it will move forward, but political surprises are always possible.
It is also worth noting that the bill maintains protections for state industrial hemp research programs (Section 530), ensuring that the hemp sector also retains its federal shield.
For now, the message from Washington is clear: The Federal government will continue to keep its hands off state-legal medical marijuana, and Congress is no longer standing in the way of federal rescheduling. After decades of stagnation, the gears of federal reform are finally, undeniably, turning.
